These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 37176648)

  • 1. Cardiometabolic Effects of Cabergoline and Combined Oral Contraceptive Pills in Young Women with Hyperprolactinemia: A Pilot Study.
    Krysiak R; Kowalcze K; Okopień B
    J Clin Med; 2023 Apr; 12(9):. PubMed ID: 37176648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autoimmune Thyroiditis Attenuates Cardiometabolic Effects of Cabergoline in Young Women With Hyperprolactinemia.
    Krysiak R; Kowalcze K; Okopień B
    J Clin Pharmacol; 2023 Aug; 63(8):886-894. PubMed ID: 37042432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vitamin D Status Determines Cardiometabolic Effects of Cabergoline in Women with Elevated Prolactin Levels: A Pilot Study.
    Krysiak R; Basiak M; Machnik G; Szkróbka W; Okopień B
    Nutrients; 2023 May; 15(10):. PubMed ID: 37242186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impaired Cardiometabolic Effects of Bromocriptine in Men With Early-Onset Androgenic Alopecia.
    Krysiak R; Basiak M; Szkróbka W; Okopień B
    J Clin Pharmacol; 2023 Mar; 63(3):345-351. PubMed ID: 36222207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiometabolic profile of young women with hypoprolactinemia.
    Krysiak R; Kowalcze K; Okopień B
    Endocrine; 2022 Oct; 78(1):135-141. PubMed ID: 35906342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cabergoline-Induced Hypoprolactinemia May Attenuate Cardiometabolic Effects of Atorvastatin: A Pilot Study.
    Krysiak R; Kowalcze K; Okopień B
    Cardiology; 2022; 147(5-6):497-506. PubMed ID: 36195057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiometabolic Risk Factors in Men with Elevated Macroprolactin Content: A Pilot Study.
    Krysiak R; Szkróbka W; Okopień B
    Exp Clin Endocrinol Diabetes; 2021 Jan; 129(1):7-13. PubMed ID: 31185509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Macroprolactinemia on Cardiometabolic Effects of Atorvastatin in Women With Hypercholesterolemia.
    Krysiak R; Kowalcze K; Okopień B
    Am J Cardiol; 2019 Oct; 124(8):1207-1212. PubMed ID: 31409451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of oral contraception on cardiometabolic risk factors in women with elevated androgen levels.
    Krysiak R; Gilowska M; Okopień B
    Pharmacol Rep; 2017 Feb; 69(1):45-49. PubMed ID: 27771529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different Effects of Atorvastatin on Cardiometabolic Risk Factors in Young Women With and Without Hyperprolactinemia.
    Krysiak R; Szkróbka W; Okopień B
    J Clin Pharmacol; 2019 Jan; 59(1):83-89. PubMed ID: 30129670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different effects of cabergoline and bromocriptine on metabolic and cardiovascular risk factors in patients with elevated prolactin levels.
    Krysiak R; Okopien B
    Basic Clin Pharmacol Toxicol; 2015 Mar; 116(3):251-6. PubMed ID: 25123447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different effects of fenofibrate on cardiometabolic risk factors in young women with and without hyperprolactinemia.
    Krysiak R; Szkróbka W; Okopień B
    Pharmacol Rep; 2019 Feb; 71(1):61-66. PubMed ID: 30469130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral contraceptive tablets containing 20 and 30 micrograms of ethinyl estradiol with 150 micrograms desogestrel. Their influence on lipids, lipoproteins, sex hormone binding globulin and testosterone.
    Akerlund M; Almström E; Högstedt S; Nabrink M
    Acta Obstet Gynecol Scand; 1994 Feb; 73(2):136-43. PubMed ID: 8116352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative metabolic effects of three types of combined oral contraceptive pills in Chinese women.
    Prasad RN; Liew D; Ratnam SS
    Contraception; 1989 Jan; 39(1):21-35. PubMed ID: 2521321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of fenofibrate on cardiometabolic risk factors in bromocriptine-treated women with mixed dyslipidemia: A pilot study.
    Krysiak R; Okrzesik J; Szkrobka W; Okopień B
    Pharmacol Rep; 2016 Feb; 68(1):185-9. PubMed ID: 26721371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative metabolic study of two low-estrogen-dose oral contraceptives containing desogestrel or gestodene progestins.
    Crook D; Godsland IF; Worthington M; Felton CV; Proudler AJ; Stevenson JC
    Am J Obstet Gynecol; 1993 Nov; 169(5):1183-9. PubMed ID: 8238183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Macroprolactinaemia modulates cardiometabolic effects of fenofibrate in men with atherogenic dyslipidaemia: A pilot study.
    Krysiak R; Kowalcze K; Okopień B
    J Clin Pharm Ther; 2020 Feb; 45(1):115-121. PubMed ID: 31444987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Impact of Atorvastatin on Cardiometabolic Risk Factors in Sisters of Women with Polycystic Ovary Syndrome.
    Krysiak R; Kowalcze K; Okopień B
    Pharmacology; 2023; 108(5):451-459. PubMed ID: 37536301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and metabolic study of a new pill containing 20 mcg ethinylestradiol plus 0.150 mg desogestrel.
    Fioretti P; Fruzzetti F; Navalesi R; Ricci C; Miccoli R; Cerri M; Orlandi MC; Melis GB
    Contraception; 1987 Mar; 35(3):229-43. PubMed ID: 2956055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiometabolic risk factors in young women with macroprolactinaemia.
    Krysiak R; Marek B; Okopień B
    Endokrynol Pol; 2019; 70(4):336-341. PubMed ID: 30845340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.